Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Capsaicin 8% patch (Qutenza®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 0412. 2012 Authors' conclusions Capsaicin patch (Qutenza®) is not recommended for use alone for the treatment of peripheral neuropathic pain (PNP) in non-diabetic adults.
Capsaicin patch (Qutenza®) is recommended as an option for restricted use within NHS Wales for the treatment of peripheral neuropathic pain (PNP) in non-diabetic adults in combination with other medicinal products for pain and in patients who have not received adequate benefit from, or are intolerant to, alternative conventional treatments.
The company submission provided evidence on the cost effectiveness of capsaicin patch (Qutenza®) as an add-on treatment in patients who were refractory to or intolerant of usual first or second line treatments.
Capsaicin patches (Qutenza®) should be administered by healthcare professionals who have completed the approved training and in a specialist clinic setting.
AWMSG is of the opinion that capsaicin patch (Qutenza®) is suitable for specialist only prescribing within NHS Wales for the above indication. Indexing Status Subject indexing assigned by CRD MeSH Administration, Cutaneous; Capsaicins; Neuralgia Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32012000342 Date abstract record published 08/08/2012 |